Treatment with EVAR has become a popular option for AAA, especially for people who are too high-risk for open surgery. Even though this technique is minimally invasive, there are worries about its impact on the kidneys and the body’s inflammatory process. The purpose of this study is to investigate the effect of EVAR on kidney and inflammatory functions in high-risk patients with AAA. The study followed high-risk patients with AAA who were scheduled for elective EVAR, tracking any changes in renal function and inflammatory markers. Serum creatinine, estimated glomerular filtration rate, C-reactive protein, interleukin-6, and white blood cell count were tested before, 48–72 hours after, and on the day of discharge. The study included patients with chronic kidney disease, diabetes mellitus, and hypertension to evaluate their vulnerability. In some patients, temporary worsening of kidney function was observed within two days of EVAR, with creatinine going up and eGFR decreasing. Most patients showed stabilization or improvement of kidney function by the discharge day, without any need for dialysis. The CRP and IL-6 markers increased significantly after surgery, reaching their peak within 24–48 hours, and then gradually returned to normal. This study showed that the response was linked to the amount of contrast and how long the procedure removed. Experiencing EVAR can result in brief renal impairment and a non-dangerous systemic inflammatory response in high-risk AAA patients. These significant changes were seen in patients, but outcomes were still positive under the care of doctors. Frequent examination of renal and inflammatory factors should be performed to identify people who need extra care as early as possible.